Swarthmore Group Inc. continued to hold its position in shares of Johnson & Johnson (NYSE:JNJ) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,725 shares of the company’s stock at the end of the third quarter. Swarthmore Group Inc.’s holdings in Johnson & Johnson were worth $2,685,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Americafirst Capital Management LLC purchased a new stake in Johnson & Johnson during the second quarter valued at about $101,000. Tuttle Tactical Management LLC purchased a new stake in Johnson & Johnson during the second quarter valued at about $103,000. Lenox Wealth Management Inc. raised its stake in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock valued at $118,000 after buying an additional 190 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. raised its stake in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock valued at $122,000 after buying an additional 690 shares in the last quarter. Finally, NCM Capital Management Group Inc. purchased a new stake in Johnson & Johnson during the second quarter valued at about $127,000. Hedge funds and other institutional investors own 64.13% of the company’s stock.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) traded down 0.57% during midday trading on Tuesday, reaching $112.48. 7,799,259 shares of the company’s stock were exchanged. Johnson & Johnson has a 12-month low of $94.28 and a 12-month high of $126.07. The firm has a 50-day moving average price of $115.97 and a 200 day moving average price of $118.40. The company has a market cap of $306.01 billion, a price-to-earnings ratio of 19.74 and a beta of 0.75.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 18th. The company reported $1.68 EPS for the quarter, topping the Zacks’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. The business earned $17.80 billion during the quarter, compared to analysts’ expectations of $17.71 billion. During the same quarter in the previous year, the company earned $1.49 EPS. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. On average, analysts expect that Johnson & Johnson will post $6.72 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be paid a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 2.84%. The ex-dividend date is Friday, November 18th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.29. Johnson & Johnson’s payout ratio is currently 56.64%.

ILLEGAL ACTIVITY WARNING: “Swarthmore Group Inc. Continues to Hold Stake in Johnson & Johnson (JNJ)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2016/11/29/swarthmore-group-inc-continues-to-hold-stake-in-johnson-johnson-jnj.html.

Several analysts recently issued reports on the stock. Barclays PLC lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $113.13 to $125.00 in a research report on Tuesday. They noted that the move was a valuation call. Bank of America Corp. reiterated a “hold” rating and set a $126.00 price target on shares of Johnson & Johnson in a research report on Monday. RBC Capital Markets set a $133.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Wednesday, November 9th. Vetr lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $117.54 price target on the stock. in a research report on Monday, November 7th. Finally, Societe Generale reiterated a “hold” rating and set a $116.00 price target on shares of Johnson & Johnson in a research report on Sunday, October 23rd. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and eight have given a buy rating to the stock. Johnson & Johnson currently has an average rating of “Hold” and a consensus target price of $121.02.

In other Johnson & Johnson news, Director Charles Prince acquired 875 shares of the business’s stock in a transaction dated Friday, October 21st. The stock was bought at an average price of $114.11 per share, with a total value of $99,846.25. Following the purchase, the director now owns 26,520 shares of the company’s stock, valued at $3,026,197.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.11% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.